Published in Semin Thromb Hemost on April 01, 2005
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev (2006) 5.28
The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood (2008) 2.22
Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivo. Blood (2009) 2.00
MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther (2005) 1.51
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face. Biochim Biophys Acta (2007) 1.29
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J (2009) 1.27
Platelets influence vascularized organ transplants from start to finish. Am J Transplant (2008) 1.08
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care (2009) 1.03
P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal (2012) 1.00
P2 receptors and platelet function. Purinergic Signal (2011) 0.98
Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS One (2011) 0.97
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One (2013) 0.91
Leukotrienes and airway inflammation. Biochim Biophys Acta (2011) 0.88
Antiplatelet drugs and the perioperative period: What every urologist needs to know. Indian J Urol (2009) 0.87
The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. Purinergic Signal (2012) 0.85
New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol (2010) 0.84
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J (2012) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Role of extracellular ATP and P2 receptor signaling in regulating renal cyst growth and interstitial inflammation in polycystic kidney disease. Front Physiol (2013) 0.79
Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Arterioscler Thromb Vasc Biol (2015) 0.79
Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention. Heart Vessels (2014) 0.79
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World J Cardiol (2015) 0.79
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem (2015) 0.78
Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int (2013) 0.78
P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential. CNS Neurol Disord Drug Targets (2012) 0.77
Deuterated clopidogrel analogues as a new generation of antiplatelet agents. ACS Med Chem Lett (2013) 0.77
Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol (2009) 0.76
Type 2 Diabetes and ADP Receptor Blocker Therapy. J Diabetes Res (2015) 0.75
Effects of thienopyridines and thienopyrimidinones on L-type calcium current in isolated cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.75
Ticlopidine in its prodrug form is a selective inhibitor of human NTPDase1. Mediators Inflamm (2014) 0.75
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Eur J Clin Pharmacol (2017) 0.75
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Conversion of human fibroblasts to angioblast-like progenitor cells. Nat Methods (2012) 1.91
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A (2009) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood (2006) 1.88
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86
The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat Struct Mol Biol (2004) 1.66
Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos (2002) 1.65
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost (2004) 1.61
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A (2006) 1.61
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol (2005) 1.30
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology (2002) 1.22
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med (2007) 1.09
A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem (2004) 1.07
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2002) 1.05
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev (2002) 1.05
Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell (2013) 1.01
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res (2003) 0.98
Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension (2009) 0.97
Involvement of peripheral benzodiazepine receptor in the oxidative stress, death-signaling pathways, and renal injury induced by ischemia-reperfusion. J Am Soc Nephrol (2004) 0.96
Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun (2002) 0.94
Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther (2003) 0.93
Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun (2004) 0.93
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell (2013) 0.91
In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol (2005) 0.90
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res (2003) 0.88
Pharmacological induction of transforming growth factor-beta1 in rat models enhances radiation injury in the intestine and the heart. PLoS One (2013) 0.87
Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine. Thromb Haemost (2002) 0.87
Functional cooperation between TrkA and p75(NTR) accelerates neuronal differentiation by increased transcription of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 activities. Exp Cell Res (2007) 0.86
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats. Eur J Pharmacol (2006) 0.86
Compound screening platform using human induced pluripotent stem cells to identify small molecules that promote chondrogenesis. Protein Cell (2012) 0.85
VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol (2004) 0.85
Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat. Cardiovasc Res (2002) 0.85
P2Y receptor antagonists in thrombosis. Curr Opin Investig Drugs (2005) 0.84
SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity. J Pharmacol Exp Ther (2002) 0.84
Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs. J Cell Physiol (2015) 0.83
AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther (2005) 0.83
In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol (2004) 0.82
Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther (2004) 0.82
SSR182289A, a selective and potent orally active thrombin inhibitor. Bioorg Med Chem (2004) 0.81
Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice. Eur J Pharmacol (2005) 0.81
The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost (2002) 0.80
Serotonin aggravates exercise-induced cardiac ischemia in the dog: effect of serotonin receptor antagonists. Eur J Pharmacol (2004) 0.79
Use of radiolabeled 2-methylthio-ADP to study P2Y receptors on platelets and cell lines. Methods Mol Biol (2004) 0.78
Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling. Cancer Cell (2016) 0.78
Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease. Blood (2010) 0.77
SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur J Pharmacol (2003) 0.77
Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol (2004) 0.77
Synthesis of Conformationally Locked Carbohydrates: A Skew-Boat Conformation of L-Iduronic Acid Governs the Antithrombotic Activity of Heparin. Angew Chem Int Ed Engl (2001) 0.77
Effects of differential blockade of the renin-angiotensin system in postinfarcted rats. Fundam Clin Pharmacol (2004) 0.75
The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine. Thromb Haemost (2003) 0.75
Development of an experimental model of pre-thrombosis in rats based on Wessler's principle using a calibrated venous stasis. Blood Coagul Fibrinolysis (2003) 0.75